Montek (Sodium Molybdate (99mo))

Sodium molybdate releases molybdate ions that become part of the molybdenum cofactor, a critical component for enzymes such as sulfite oxidase, xanthine oxidase, and aldehyde oxidase. These enzymes catalyze oxidation‑reduction reactions essential for sulfur‑amino acid metabolism, purine breakdown, and detoxification processes.

The dosage of Montek is determined by the prescribing clinician based on the patient’s specific condition, laboratory values, and route of administration. Healthcare professionals calculate the appropriate amount to achieve therapeutic molybdenum levels while minimizing the risk of adverse effects.

Safety data for sodium molybdate in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant. Clinicians should discuss individual circumstances with the patient and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the Montek product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Montek provides sodium molybdate in an injectable form suitable for intravenous and ocular use, offering rapid bioavailability compared with oral molybdenum supplements. This can be advantageous in acute deficiency or when precise dosing is required for diagnostic procedures, whereas oral formulations may be preferred for chronic supplementation.

Montek should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and potency throughout its shelf life.

Montek is administered by a qualified healthcare professional either as an intravenous infusion or as an ocular injection, depending on the therapeutic indication. The exact administration technique, rate, and volume are determined by the prescriber and follow standard aseptic procedures.

Serious risks include severe allergic reactions such as anaphylaxis, rare skin conditions like Stevens‑Johnson syndrome, and potential liver or kidney impairment in susceptible individuals. Prompt recognition and medical intervention are essential if any of these serious adverse events occur.

Montek should be avoided in patients with a known hypersensitivity to sodium molybdate or any of its excipients. Individuals with severe renal or hepatic impairment should use it only under close medical supervision, and it is contraindicated during pregnancy unless the benefits outweigh the risks.